Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …

Background CARs are simulated receptors containing an extracellular single-chain variable
fragment (scFv), a transmembrane domain, as well as an intracellular region of …

Adoptive cell therapy with genetically modified T cells has generated exciting outcomes in
hematologic malignancies, but its application to solid tumors has proven challenging. This …

Adoptive therapy using chimeric antigen receptor-modified T cells (CAR-T cells) is effective
in hematologic but not epithelial malignancies, which cause the greatest mortality. In breast …

Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell
therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell …

The successful outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating
hematologic cancers have increased the previously unprecedented excitement to use this …

Adaptive immunity, orchestrated by B-cells and T-cells, plays a crucial role in protecting the
body from pathogenic invaders and can be used as tools to enhance the body's defense …

Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …

Chimeric antigen receptor (CAR)-T cell therapy represents a landmark advance in
personalized cancer treatment. CAR-T strategy generally engineers T cells from a specific …

Integrins are transmembrane receptors that have been implicated in the biology of various
human physiological and pathological processes. These molecules facilitate cell …